Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 20, 2026, 2:03 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 265–288 of 488 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Promethazine Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

Safety, Pharmacokinetics and Pharmacodynamics Study of Treatment With CHF 5074 in Healthy Young Male Subjects

NCT00954252
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
CHF 5074, placebo
Drug
Lead sponsor
CERESPIR
Industry
Eligibility
18 Years to 45 Years · Male only
Enrollment
84 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
1
States / cities
Eatontown, NJ 07724, New Jersey
Source: ClinicalTrials.gov public record
Updated Feb 10, 2015 · Synced Oct 20, 2026, 2:03 PM EDT
Withdrawn Early Phase 1 Interventional

Melphalan on Disease Burden Measured by Next Generation Sequencing Before AHCT (Autologous Hematopoietic Cell Transplant) for Multiple Myeloma

NCT05013437
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Evomela, Next Generation Sequencing, Prochlorperazine, Acetaminophen, Diphenhydramine
Drug · Device
Lead sponsor
Koen van Besien
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 2, 2024 · Synced Oct 20, 2026, 2:03 PM EDT
Completed Not applicable Interventional Results available

Randomized Trial of the Effectiveness of Topical "ABH Gel" vs. Placebo in Cancer Patients With Nausea

NCT01556932
View directory record Official record
Conditions
Nausea, Vomiting
Interventions
ABH gel, placebo
Drug · Other
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Oct 16, 2015 · Synced Oct 20, 2026, 2:03 PM EDT
Terminated Phase 2 Interventional Results available

Diphenhydramine, Lorazepam, and Dexamethasone in Treating Nausea and Vomiting Caused By Chemotherapy

NCT00429702
View directory record Official record
Conditions
Nausea, Vomiting, Unspecified Childhood Solid Tumor, Protocol Specific
Interventions
Decadron®, Benadryl®, Ativan®, ondansetron hydrochloride
Drug
Lead sponsor
University of South Florida
Other
Eligibility
8 Years to 18 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
6
States / cities
Fort Myers, Florida • Orlando, Florida • Tampa, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 25, 2014 · Synced Oct 20, 2026, 2:03 PM EDT
Completed Phase 2 Interventional

Fludarabine, Rituximab, and Alemtuzumab for B-Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

NCT00143065
View directory record Official record
Conditions
Lymphoma, Small Lymphocytic, Lymphocytic Leukemia, Chronic
Interventions
Fludarabine, Rituximab, Alemtuzumab
Drug
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 8, 2017 · Synced Oct 20, 2026, 2:03 PM EDT
Completed Phase 3 Interventional

Irbesartan/Hydrochlorothiazide (HCTZ) Combination Therapy for Patients With Moderate Hypertension

NCT00095550
View directory record Official record
Conditions
Hypertension
Interventions
Irbesartan/HCTZ, Irbesartan monotherapy, HCTZ monotherapy
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
496 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
87
States / cities
Birmingham, Alabama • Columbiana, Alabama • Mesa, Arizona + 84 more
Source: ClinicalTrials.gov public record
Updated Apr 15, 2011 · Synced Oct 20, 2026, 2:03 PM EDT
Terminated Phase 3 Interventional Results available

A Study to Evaluate the Safety of Rituximab Retreatment in Subjects With Systemic Lupus Erythematosus

NCT00381810
View directory record Official record
Conditions
Lupus Erythematosus, Systemic
Interventions
Rituximab, Methylprednisolone, Acetaminophen, Diphenhydramine
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
16 Years to 75 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
11
States / cities
Paradise Valley, Arizona • San Leandro, California • Boise, Idaho + 8 more
Source: ClinicalTrials.gov public record
Updated Aug 1, 2017 · Synced Oct 20, 2026, 2:03 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Pilot Study of Losartan and N-acetylcysteine as Inhibitors of Muscle Oxidative Stress in Elderly

NCT01384591
View directory record Official record
Conditions
Aging
Interventions
N-acetylcysteine, Losartan, Placebo losartan, Placebo N-acetylcysteine
Drug
Lead sponsor
The University of Texas Medical Branch, Galveston
Other
Eligibility
60 Years to 85 Years
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2015
U.S. locations
1
States / cities
Galveston, Texas
Source: ClinicalTrials.gov public record
Updated May 8, 2018 · Synced Oct 20, 2026, 2:03 PM EDT
Terminated Phase 2 Interventional

A Phase II Study of Vibecotamab (XmAb14045) for MRD- Positive AML and MDS After Hypomethylating Agent Failure

NCT05285813
View directory record Official record
Conditions
AML, MDS
Interventions
Vibecotamab, Dexamethasone, Acetaminophen, Diphenhydramine
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 22, 2026 · Synced Oct 20, 2026, 2:03 PM EDT
Terminated Phase 2 Interventional

Inotuzumab Ozogamicin for Children With MRD Positive CD22+ Lymphoblastic Leukemia

NCT03913559
View directory record Official record
Conditions
Acute Lymphoblastic Leukemia
Interventions
Inotuzumab ozogamicin, Methotrexate, Hydrocortisone, Cytarabine, Diphenhydramine, Acetaminophen, Methylprednisolone
Drug
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
Up to 21 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
2
States / cities
San Diego, California • Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Feb 12, 2026 · Synced Oct 20, 2026, 2:03 PM EDT
Completed Phase 4 Interventional

A Comparison of the Effect of Olmesartan Medoxomil, Losartan Potassium, and Atenolol on the Ability of Overweight Patients With High Blood Pressure to Respond to Insulin

NCT00185094
View directory record Official record
Conditions
Hypertension, Insulin Resistance, Metabolic Syndrome
Interventions
Olmesartan medoxomil, Losartan potassium, Atenolol
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years to 75 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
10
States / cities
Birmingham, Alabama • San Diego, California • Miami, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Dec 23, 2005 · Synced Oct 20, 2026, 2:03 PM EDT
Completed Not applicable Interventional Results available

A Cost Effective Treatment for Headache in Pregnancy When Acetaminophen Alone is Ineffective.

NCT02295280
View directory record Official record
Conditions
Headache
Interventions
Metoclopramide, Diphenhydramine, Codeine
Drug
Lead sponsor
St. Louis University
Other
Eligibility
16 Years to 50 Years · Female only
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Apr 2, 2018 · Synced Oct 20, 2026, 2:03 PM EDT
Completed Phase 2 Interventional Results available

Losartan for Patients With COVID-19 Requiring Hospitalization

NCT04312009
View directory record Official record
Conditions
Corona Virus Infection, Acute Respiratory Distress Syndrome, SARS-CoV Infection
Interventions
Losartan, Placebo
Drug · Other
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years and older
Enrollment
205 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
13
States / cities
Gainesville, Florida • Jacksonville, Florida • Atlanta, Georgia + 8 more
Source: ClinicalTrials.gov public record
Updated Jun 29, 2022 · Synced Oct 20, 2026, 2:03 PM EDT
Completed Phase 1 Interventional Results available

CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory CD19/CD22-expressing B Cell Malignancies

NCT03448393
View directory record Official record
Conditions
Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, B Cell, B-Cell Lymphoma, B-Cell Leukemia, Acute Lymphoid Leukemia, B-Non Hodgkin Lymphoma, B-NHL, B-All, Acute Lymphoblastic Leukemia, Acute Lymphocytic Leukemia
Interventions
CD19/CD22 CAR T-Cells, Fludarabine, Cyclophosphamide, Apheresis, Anti-emetic, Diphenhydramine, Acetaminophen, ECG, ECHO, MRI Brain, Bone marrow biopsy, Cardiac MRI
Biological · Drug · Procedure + 2 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
3 Years to 39 Years
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 4, 2025 · Synced Oct 20, 2026, 2:03 PM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Intravenous Fluids in Pediatric Migraine

NCT06182098
View directory record Official record
Conditions
Migraine, Migraine in Children
Interventions
1/2 maintenance fluids, Ketorolac, Diphenhydramine, Prochlorperazine, bolus
Other · Drug
Lead sponsor
Dayton Children's Hospital
Other
Eligibility
5 Years to 21 Years
Enrollment
134 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
1
States / cities
Dayton, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 26, 2023 · Synced Oct 20, 2026, 2:03 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Evaluate Analgesic / Sedative Efficacy of Naproxen Sodium and Diphenhydramine in Patients With Postsurgical Dental Pain

NCT01495858
View directory record Official record
Conditions
Pain, Postoperative
Interventions
Naproxen Sodium 440 mg / DPH 25 mg (BAY98-7111), Naproxen Sodium 440 mg (BAYH6689), DPH 50 mg
Drug
Lead sponsor
Bayer
Industry
Eligibility
12 Years and older
Enrollment
267 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
2
States / cities
Austin, Texas • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jun 8, 2015 · Synced Oct 20, 2026, 2:03 PM EDT
Completed No phase listed Observational

Replication of the TRANSCEND Antihypertensive Trial in Healthcare Claims Data

NCT04354376
View directory record Official record
Conditions
Hypertension
Interventions
Loop diuretics, thiazides, dihydropyridines, Telmisartan
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
55 Years and older
Enrollment
40,048 participants
Timeline
2017 – 2021
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 27, 2023 · Synced Oct 20, 2026, 2:03 PM EDT
Terminated Early Phase 1 Interventional

Tissue Pharmacokinetics of Intraoperative Gemcitabine in Resectable Adenocarcinoma of the Pancreas

NCT01276613
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
Gemcitabine, Losartan
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2019
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 2, 2019 · Synced Oct 20, 2026, 2:03 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Crossover Bioequivalence Study of Irbesartan Hydrochlorothiazide 300/25 mg Tablets Under Fed Conditions

NCT01712126
View directory record Official record
Conditions
Hypertension
Interventions
Irbesartan and Hydrochlorothiazide, Avalide
Drug
Lead sponsor
Roxane Laboratories
Industry
Eligibility
18 Years to 45 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jan 23, 2018 · Synced Oct 20, 2026, 2:03 PM EDT
Completed Phase 3 Interventional Results available

Study to Explore the Mechanism of Action of Ocrelizumab and B-Cell Biology in Participants With Relapsing Multiple Sclerosis (RMS) or Primary Progressive Multiple Sclerosis (PPMS)

NCT02688985
View directory record Official record
Conditions
Relapsing Multiple Sclerorsis, Multiple Sclerosis, Primary Progressive
Interventions
Ocrelizumab, Lumbar Puncture, Methyloprednisolone, Antihistamine
Drug · Procedure
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
131 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
12
States / cities
Palo Alto, California • San Francisco, California • Aurora, Colorado + 9 more
Source: ClinicalTrials.gov public record
Updated Jun 4, 2024 · Synced Oct 20, 2026, 2:03 PM EDT
Completed Phase 2 Interventional Results available

Non-myeloablative Allogeneic Transplantation for the Treatment of Multiple Myeloma

NCT00185614
View directory record Official record
Conditions
Blood Cancer, Multiple Myeloma
Interventions
Autologous hematopoietic cell transplant (Auto-HCT), Allogeneic hematopoietic cell transplant (Allo-HCT), Cyclophosphamide, Filgrastim, Melphalan, Total body irradiation (TBI), Cyclosporine (CSP), Mycophenolate Mofetil (MMF)
Procedure · Drug · Radiation
Lead sponsor
Wen-Kai Weng
Other
Eligibility
18 Years to 70 Years
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2010
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Jan 18, 2018 · Synced Oct 20, 2026, 2:03 PM EDT
Completed Phase 2 Interventional Results available

A Study of Biweekly Gemcitabine, Paclitaxel, and Avastin in Patients With Metastatic Breast Cancer

NCT00618826
View directory record Official record
Conditions
Metastatic Breast Cancer
Interventions
Paclitaxel, Gemcitabine, Avastin
Drug
Lead sponsor
Barbara Ann Karmanos Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2014
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Apr 14, 2017 · Synced Oct 20, 2026, 2:03 PM EDT
Completed Phase 1 Interventional

Phase I Study of PI3(Phosphoinositol 3)-Kinase Inhibitor BAY80-6946 With Paclitaxel in Patients With Advanced Cancer

NCT01411410
View directory record Official record
Conditions
Neoplasms
Interventions
Paclitaxel, Copanlisib (BAY80-6946)
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
3
States / cities
St Louis, Missouri • New York, New York • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 11, 2017 · Synced Oct 20, 2026, 2:03 PM EDT
Completed Phase 2 Interventional Results available

Standard Infusion Carboplatin Versus Prophylactic Extended Infusion Carboplatin in Patients With Patients With Recurrent, Ovary, Fallopian Tube, and Primary Peritoneal Cancer

NCT01248962
View directory record Official record
Conditions
Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer
Interventions
carboplatin
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
21 Years and older · Female only
Enrollment
146 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2018
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 2, 2019 · Synced Oct 20, 2026, 2:03 PM EDT